A phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with meningococcal C conjugate vaccine induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix) vaccine, in healthy children six to 12 years of age
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Hib-meningococcal vaccine group C conjugate (Primary)
- Indications Haemophilus infections; Meningococcal group C infections
- Focus Pharmacodynamics
- 15 Jul 2010 New source identified and integrated (United Kingdom Clinical Research Network).
- 10 May 2007 New trial record.